A Medical Device Daily

Wound Management Technologies (Fort Worth, Texas) has signed an agreement with Med Pro Associates of Colorado (Idaho Springs, Colorado) to serve as a non-exclusive independent sales and marketing representative to solicit sales, obtain orders and provide sales and marketing support for the company's line of products within the U.S.

Under terms of the agreement, Med Pro will market and sell Wound Management Technologies' CellerateRx and other products on a non-exclusive basis throughout the U.S. The initial focus will be on Wound Management Technologies' major product, CellerateRx, which is used in the management of pressure ulcers, traumatic wounds, diabetic ulcers, first and second degree burns, venous stasis ulcers, ulcers due to arterial insufficiency and superficial wounds. CellerateRx's patented collagen fragments, which are a fraction of the size of the native collagen molecules and particles found in other products, deliver the benefits of collagen to the body immediately.

Wound Management Technologies CEO Scott Haire said, "This agreement with Med Pro will enable us to offer CellerateRx and other products to hospitals and doctors' offices in all 50 states. Med Pro has a well established and effective sales and marketing network that we expect will substantially increase our sales."

Cathy Bradshaw, president of Wound Management's Wound Care Innovations subsidiary, said, "WCI is excited to have Med Pro representatives marketing CellerateRx extensively throughout the country. We continue to see great results with CellerateRx and have positive feedback from physicians. Our studies continue to support the effectiveness of CellerateRx and having the Med Pro team presenting CellerateRx will increase our exposure and increase sales."

In other agreements and contracts news:

The development of a proton therapy center in the Pacific Northwest has taken a significant step forward with the signing of a letter of intent between the Seattle Cancer Care Alliance (SCCA; Seattle) and ProCure Treatment Centers (Bloomington, Indiana). SCCA and ProCure said they are working to bring this advanced form of radiation therapy to adult and pediatric cancer patients.

"The SCCA was formed to accelerate the development and evaluation of new therapies for cancer, and then make those therapies more widely available in our region. Proton therapy has emerged as a compelling treatment for pediatric and many adult cancer patients, who would currently have to leave the Northwest for proton therapy or may not have access to it at all. We're also excited to be working with ProCure to further develop this technology and to identify new areas where protons can be an effective and appropriate treatment," said Norm Hubbard, SCCA executive vice president.

The SCCA proton center will be built on the campus of Northwest Hospital & Medical Center in north Seattle.

• HealthEdge (Burlington, Massachusetts), a provider of an enterprise-class software platform for healthcare payers, reported a partnership with Bloodhound Technologies. Through this alliance, users of HealthEdge's HealthRules product suite will gain the ability to realize improved claim efficiency, faster issue resolution, greater overpayment savings, and fraud detection using Bloodhound Technologies' ConVergence Point service.

"Our partnership with HealthEdge offers payers a comprehensive approach to eliminating manual claims processes and maximizing reimbursement accuracy, which is particularly important in today's cost-conscious economy," said Gary Twigg, president/CEO of Bloodhound Technologies.

• Premier Purchasing Partners (Charlotte, North Carolina) has selected AeroScout (Redwood City, California) as the sole source provider of RFID Asset Tracking and Management solutions for Premier's ASCEND program. The three-year agreement covers AeroScout's Wi-Fi RTLS healthcare visibility solutions for all ASCEND members. AeroScout's solutions will leverage ASCEND members' standard Wi-Fi networks and offer a broad range of applications and capabilities that deliver strong returns for hospital organizations. ASCEND (Accelerated Supply Chain Endeavor) is designed to help healthcare providers achieve and sustain rapid improvements in supply chain performance.

Premier also reported that Bon Secours St. Francis Medical Center (Midlothian, Virginia) selected Premier's SafetySurveillor Web-based infection tracking and antimicrobial utilization tool. More than 270 hospitals use SafetySurveillor to help prevent healthcare-associated infections and optimize antibiotic use, thereby protecting patients more effectively while safely reducing hospital costs.

• OSI Systems (Hawthorne, California) reported that its Spacelabs Healthcare division has received a follow-on contract for a broad range of patient monitoring products from an undisclosed U.S. regional hospital totaling about $2 million. The systems are to be installed throughout the hospital including the critical care, preoperative, OR and outpatient surgery areas to provide comprehensive monitoring of patients throughout the care cycle.

• Solos Endoscopy (Boston) has received purchase orders for the MammoView line of surgical endoscopy instruments from Beth Israel Medical Center (New York). "We are proud to be a supplier to such a prestigious healthcare provider. The Beth Israel Medical Center has been serving New York City for over 100 years and we look forward to creating a long term relationship with the organization," said Bob Segersten, president of Solos Endoscopy.

Impulse Monitoring (Columbia, Maryland), a provider of intraoperative neurophysiological monitoring (IONM) services to hospitals, reported that it has signed an agreement with the Vanderbilt University Medical Center (VUMC; Nashville) to provide comprehensive IONM overflow support to VUMC's in-house neuromonitoring team. IMI's services will include real-time, onsite monitoring by certified neurophysiologist technicians. IONM assesses neurological function involving the brain, spinal cord and related nerve structures during such surgeries. Use of IONM facilitates the surgical process and can reduce surgical risk by providing alerts to surgeons of potential harm to the spinal cord or neural structures.